RxDoctor Payments Data

Matthew Ziegelmann, MD

Urology · Rochester, MNNPI 1386080018

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Endo Pharmaceuticals Inc. at 49.6% of the total. Reporting peaked in 2022 at $5,122 and has fallen 90.1% since, to $507 in 2025.

$9,274in general payments, 2019–2025

Across 68 payments — averaging $136.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$5K
  • Coloplast$3K
  • Boston Scientific$2K
  • Axonics, Inc.$71
  • AstraZeneca$35
$46,913in research payments, 2019–2025

Across 8 payments — averaging $5864.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo USA, Inc.$26K
  • Endo Pharmaceuticals Inc.$18K
  • Coloplast$3K

What the payments were for

  • Consulting fees$5,22556%
  • Travel & lodging$771%
  • Food & beverage$3,93642%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Endo Pharmaceuticals Inc.3$4,596
Coloplast41$2,754
Boston Scientific22$1,818
Axonics, Inc.1$71
AstraZeneca1$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,274 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$284,413
Medicare patients
359
Services billed
4,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →